UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000024052
Receipt number R000027694
Scientific Title Safety evaluation of an excessive consumption of Longvida
Date of disclosure of the study information 2016/10/01
Last modified on 2018/02/14 13:17:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Safety evaluation of an excessive consumption of Longvida

Acronym

Safety evaluation of an excessive consumption of Longvida

Scientific Title

Safety evaluation of an excessive consumption of Longvida

Scientific Title:Acronym

Safety evaluation of an excessive consumption of Longvida

Region

Japan


Condition

Condition

Nothing (healthy subject)

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety of excessive consumption of Longvida

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

physical examination
Hematologic test
blood biochemical test
urine analysis
Doctor's questions
adverse events

Key secondary outcomes

Questionnaires


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Longvida 2000mg/day, 4weeks

Interventions/Control_2

Placebo, 4weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >

Gender

Male and Female

Key inclusion criteria

1. Healthy Japanese males and females
2. BMI>=18.5 and <25 kg/m2
3. Subjects who are judged as appropriate for the study by the principal investigator

Key exclusion criteria

1. Subjects who have at least one previous medical history of malignant tumor, heart failure or myocardial infarction
2. Subjects who are patient or have history of cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension or other chronic diseases
3. Subjects who have undergone gastrointestinal tract surgery; except appendectomy
4. Subjects who are currently taking medicines (include herbal medicines) and/or supplements
5. Subjects who are allergic to medicines or the test material of this trial
6. Subjects who are or are possibly pregnant, or are lactating
7. Subjects who participate in other clinical trials in the past 3 months
8. Subjects who work time is irregular
9. Subjects who have been determined ineligible by principal investigator for other reasons

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yutaka Kondo

Organization

Omnica Co.,Ltd

Division name

Research and development Dept.

Zip code


Address

TN Koishikawa BLDG. 5F, 1-15-17 Koishikawa, Bunkyo-ku, Tokyo, JAPAN

TEL

03-5840-9815

Email

kondo@omnica.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Satomi Iwata

Organization

Omnica Co.,Ltd

Division name

Research and development Dept.

Zip code


Address

TN Koishikawa BLDG. 5F, 1-15-17 Koishikawa, Bunkyo-ku, Tokyo, JAPAN

TEL

03-5840-9815

Homepage URL


Email

iwata@omnica.co.jp


Sponsor or person

Institute

ORTHOMEDICO, Inc.

Institute

Department

Personal name



Funding Source

Organization

Omnica Co.,Ltd

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団 盛心会 タカラクリニック (東京都)


Other administrative information

Date of disclosure of the study information

2016 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 09 Month 13 Day

Date of IRB


Anticipated trial start date

2016 Year 09 Month 19 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 09 Month 14 Day

Last modified on

2018 Year 02 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027694


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name